#79 NL-IL Coronavirus R&D opportunity: Search for in-vitro system for SARS-Cov-2 under BSL3 conditions
- Location De Bilt
- Industry Life sciences and health
- Online since 2020-03-19
A Dutch company with presence in Israel, is looking for an in-vitro system for SARS-Cov-2. The company specializes in anti-HIV peptide Cancer treatment Apoptosis
Zion medical, a Dutch company with a presence in Israel, is developing AIDS and Cancer curing products based on peptides derived from HIV and targeted Lenti-viral particles. Zion medical has made a breakthrough in HIV & Cancer treatment. With biological targeting of our curing products to the infected cells as well to the cancer cells, we promote specifically the death of the HIV infected and cancer cells, in a safe manner with minimum side effects. The company aimed to contribute to the world effort curing COVID-19, thus looking for an in-vitro system for SARS-Cov-2. This cell-based assay requires BSL3, hoping there are labs that can provide such services.
Contact details: Eynat Finkelshtein, Chief Scientific Officer, Zion Medical: eynat@zionmedical.com
Go to website